🚨 New data at #ASCO2026: First-in-class RNA-targeting therapy #STC15 shows early activity in #sarcoma.
📅 June 1, 1:30–4:30 PM CDT
🔗 Read more: bit.ly/3PwODTa
📅 June 1, 1:30–4:30 PM CDT
🔗 Read more: bit.ly/3PwODTa
Storm Therapeutics
@storm_tx
STORM Therapeutics is a biotech company discovering and developing novel small molecule therapies for RNA modification enzymes for oncology and other diseases
396 Following 969 Followers 269 Posts
Latest posts 5
📢 We’ve announced a $56 million Series C financing to support the advancement of STC‑15, our first‑in‑class, oral small‑molecule METTL3 inhibitor. The first patient has now been dosed in a Phase 2 monotherapy trial in selected sarcoma indications. bit.ly/3QeVxMH
Excited to team up with AlidaBio to explore how METTL3 inhibition affects RNA regulation in cancer patients. We're using AlidaBio's advanced sequencing platforms to analyze samples from our Phase 1/2 trials with STC-15, our first-in-class METTL3 inhibitor. bit.ly/49tpJd5
Meet STORM at @ELRIG_SCIENCE Drug Discovery 2025!
Join us for our poster presentations to explore the critical role of RNA-binding proteins in cellular replication stress mechanisms.
📍 Poster #163
📅 21 & 22 Oct
🕐 13:00-13:45 BST
📌 Beside the Tech Theatre
Join us for our poster presentations to explore the critical role of RNA-binding proteins in cellular replication stress mechanisms.
📍 Poster #163
📅 21 & 22 Oct
🕐 13:00-13:45 BST
📌 Beside the Tech Theatre
📢 Discovery data to be unveiled at AACR-NCI-EORTC 2025 📢
STORM Therapeutics will present new data on #STM11315, its allosteric, potent & selective #DHX9 helicase inhibitor, on 24 October.
🗣️ Oral Presentation: 5:26–5:36 PM EDT
📌 Poster Presentation: 12:30–4:00 PM EDT
STORM Therapeutics will present new data on #STM11315, its allosteric, potent & selective #DHX9 helicase inhibitor, on 24 October.
🗣️ Oral Presentation: 5:26–5:36 PM EDT
📌 Poster Presentation: 12:30–4:00 PM EDT